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Abstract
BACKGROUND: Cough-variant asthma (CVA) is a type of asthma in which the main symptom is a dry, non-productive 
cough.
OBJECTIVE: The objective of the study was to evaluate the therapeutic effect of Montelukast in CVA and to 
investigate the prevalence of Montelukast in CVA.
METHODS: A cross-sectional study was conducted on 30 patients with chronic cough at least 8 weeks using 
Montelukast at Al-Kindy Hospital over the period of January 2018‒March 2018. An interview using questionnaire was 
used to collect the data that were specifically prepared to meet the objective of study including age, sex, associated 
disease, exacerbation factors, and classical therapy.
RESULTS: There was a reduction of the symptoms associated with CVA after treatment with Montelukast. The 
prevalence of exacerbation factors was as follows: Dust (73.3%) of patients, food (36.7%), exercise (60%), 
psychological (56.7%), smoking (30%), and others (perfume and cold weather) (26.7%). The usage of Montelukast 
in this study was 73.3% (22 patients). Patients using Montelukast have shown improvement of symptoms as follows: 
Chest pain was relieved from 57.1% of patients, exhaustion (58.3%), vomiting (76.5%), sleep disturbance (54.5%), 
affecting daily life in 57.1%, and syncope 66.7%.
CONCLUSION: The prevalence of Montelukast administration to the patients with chronic cough in our study was 
found to be more than 70% of the 30 total patients. Montelukast usage leads to reduction in the frequency of chronic 
cough and the symptoms associated with it.
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Introduction
Cough-variant asthma (CVA) is a type of 
asthma that is marked by a dry, non-productive chronic 
cough that lasts from 6 to 8 weeks. Mostly, it is nocturnal 
cough. In some cases, patients develop daytime cough 
as bad as nighttime cough, but have no other traditional 
asthma symptoms such as wheezing or shortness of 
breath. It does not include some of the other defining 
symptoms of asthma, such as chest tightness, wheezing 
when exhaling, shortness of breath, fluid in the lungs, 
productive cough, and trouble sleeping due to any of the 
above symptoms. Anyone can get CVA at any time, but 
it is common in young kids with childhood asthma [1]. 
People with CVA asthma often notice that coughing 
increases with exercise. Coughing may increase 
when they are exposed to asthma triggers or allergy 
causing substances such as dust or strong fragrances 
or when they are in cold air. Coughing of CVA may be 
due to bronchoconstriction, but the detailed causal 
relationship involved in cough and bronchoconstriction 
remains unknown. If left untreated, CVA can progress 
into more severe, chronic asthma. A recent study 
noted that “30‒40% of adult patients with CVA, unless 
adequately treated, may progress to classic asthma.” 
Another study indicated that CVA is one of the most 
common causes of coughing worldwide [2].
Pathophysiology
During a CVA and asthma episode, the airways 
narrow and produce excess mucus, making it difficult 
to breathe. In essence, all types of asthma are the 
result of an immune response in the bronchial airways. 
The airways of asthma patients are “hypersensitive” 
to certain triggers, also known as stimuli. It is 
usually classified as type I hypersensitivity. In type I 
hypersensitivity, B-lymphocytes are stimulated by 
CD4+ TH2 to produce IgE antibodies specific to an 
antigen. Inhalation of antigens stimulates induction 
of TH2-type cells and releases interleukins IL-4 
and IL-5. This leads to synthesis of IgE that binds to 
mucosal mast cells. Exposure of IgE-coated mast 
cells to the same antigen causes cross-linking of IgE 
and the release of chemical mediators [3]. In response 
to exposure to these triggers, the bronchi contract 
into spasm. Inflammation soon follows, leading to a 
further narrowing of the airways and excessive mucus 
production, which leads to coughing [4]. Bronchospasm 
may resolve spontaneously in 1–2 h, or in about 50% of 
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subjects, may become part of a “late” response, where 
this initial insult is followed 3–12 h later with further 
bronchoconstriction and inflammation [4].
Montelukast (Singulair™) is a cysteinyl 
leukotriene receptor antagonist, used for the 
maintenance treatment of asthma and to relieve 
symptoms of seasonal allergies and exercise-induced 
bronchospasm [5]. It acts by blocking the action of 
leukotriene D4 (and secondary ligands and leukotrienes 
C4 and E4) on the cysteinyl leukotriene receptor 1 
(Cys-LTR1) in the lungs and bronchial tubes by binding 
to it [6].
Objective
This study was performed to evaluate the 
therapeutic effect of Montelukast in CVA and to measure 
the prevalence of Montelukast in usage CVA patients.
Methods
A cross-sectional study was conducted at 
Al-Kindy Teaching Hospital between the periods of 
January 2018 and April 2018. The patients were 
diagnosed by the Internal Medicine Consultant Clinic 
to have CVA. Patients were excluded if they have 
pregnancy, diabetes mellitus, heart failure, and drugs 
that may induce cough, for example, captopril. A 
convenient method of sampling was used in this study. 
Thirty patients with chronic cough (without wheezing and 
shortness of breath) for at least 8 weeks were recruited 
in the study. Then, Montelukast was administered for 
4 weeks as 10 mg oral dose tablet, once daily. The study 
protocol was approved by our institutional review board 
and conformed to the principles of the Declaration of 
Helsinki. After obtaining formal written consent from 
each patient, an interview using questionnaire was held 
to collect the data that were specifically prepared to meet 
the objectives of study including (age, sex, associated 
disease, and exacerbation factors). The data were 
prepared as frequencies and relative frequencies.
Results
Thirty patients participated in the study. Table 1 
shows the number and percentage of patients in each 
demographic characteristic such as gender, occupation, 
and marital status. Males and females were nearly equal 
in number, jobless patients were more than employed 
patients, and married and unmarried patients are much 
nearly equal.
Table 2 shows the number and percentage of 
patients in each age group. The group which contained 
the largest number of patients was 41‒59 years. The 
groups which contained the least number of patients 
were 17‒25 and 26‒40 years.
Table 2: Number of patients in different age groups (years)
Age groups (years) Frequency Relative frequency (%)
6‒16 9 30.0
17‒25 4 13.3
26‒40 4 13.3
41‒59 10 33.3
60‒70 3 10.0
Total 30 100.0
Figure 1 shows the number and percentage of 
patients who have certain exacerbation factors. Dust was 
the most prevalent exacerbation factor in this study, while 
other factors (perfumes) were the least prevalent factor.
Figure 1: Prevalence of exacerbation factors among patients
Table 3 shows the number of patients who use 
Montelukast in different age groups were 6‒16, 17‒25, 
26‒40, 41‒59, and 60‒70 years.
Table 3: Montelukast use in different age groups (years)
Age groups (years) Montelukast use Total
Yes No
6‒16 9 0 9
17‒25 3 1 4
26‒40 2 2 4
41‒59 8 2 10
60‒70 0 3 3
Total 22 8 30
Figure 2 shows the number and percentage of 
patients who used Montelukast and benefited from it. 
Vomiting patients showed the most benefit and syncope 
patients showed the least.
Figure 2: Patients benefited from Montelukast
Table 1: Number of patients in different demographic characteristics
Demographic parameters Frequency Relative frequency (%)
Gender
Male 13 43.3
Female 17 56.7
Occupation
Employed 11 36.7
Jobless 19 63.3
Marital status
Married 16 53.3
Unmarried 14 46.7
Address
Rural 5 16.7
Urban 25 83.3
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Discussion
Most of this study patients were living in 
urban areas, urban areas are known to have more 
industrialization and pollution, and this agrees with a 
study done by Hirshon et al. (2006), in which Maryland 
showed the highest rates of emergency department visits 
for chronic cough in urban areas [7]. A study performed 
by Sole et al. (2007) showed that the international 
prevalence of chronic cough-related symptoms was 
higher among those adolescents living in the urban 
centers in comparison to the rural ones in Brazil [8].
Dust was an exacerbation factor that more than 
two-thirds of patients in this study were complaining 
from, this agrees with a study by Tricia (1977), in which 
it suggests that dust exposure can have long-lasting 
effects on respiratory symptoms in chronic dry cough. 
More than half of this study patients had exercise to 
be a triggering exacerbation factor. An article was 
published by Khajotia et al. (2008) claims that 90% 
of asthmatic individuals and 35‒45% of patients with 
allergic rhinitis are afflicted by exercise-induced asthma, 
while 3–10% of the general population is also believed 
to suffer from this condition. In this study, 18 patients 
were suffering from this condition and based on Leff 
et al. (1998) stated that Montelukast usage as a therapy 
offers significantly greater protection against exercise-
induced bronchoconstriction. Just after 12 weeks of 
Montelukast administration, patients have shown better 
control of their state without the need of B-agonist 
during or after exercise challenge [9]. Smoking was an 
exacerbation factor in a number of the study patients. 
A review conducted by Stapleton et al. (2011), has 
shown patients who smoke, and has poorer control than 
asthmatic nonsmokers. Airway mucosal permeability is 
increased in smokers, which could lead to an increased 
clearance of inhaled corticosteroids from the airways so 
in conclusion, cigarette smoking and passive smoking 
in asthmatics lead to detrimental effects in patient 
outcomes and effectiveness of steroid therapy [10]. 
In our study, other exacerbation factors were found to 
be the psychological condition of patients, in which a 
patient may develop a persistent cough in the absence 
of physical factors associated with respiratory system, 
but it occurs alongside with anxiety and stress. In 
a study that was published in 2018 by Wright MFA1, 
Balfour-Lynn IM1, found that 18% of the chronic cough 
patient included in their study were actually suffering 
from behavioral/psychiatric cough [11].
In Figure 2, chest pain was experienced by 
most patients in this study. After the administration 
of Montelukast, more than half showed an improving 
result due to the medication. A clinical trial was utilized 
by Al-Hamdani (2010) to evaluate the outcome of 
using Montelukast showed that patients who used 
Montelukast had their asthma symptom, chest 
wheezing, and pulmonary function test (PFT) values 
significantly improved at the end of the study compared 
to the first visit. All symptoms were significantly lower 
and PFT values were higher in the 2nd group compared 
to the 1st group. In conclusion, Montelukast sodium 
showed significant changes in asthma symptoms and 
PFT after 1 month of treatment [12]. Sleep disturbance 
or sleep apnea is a symptom that three-fourths of our 
patients suffered from, and about half of them improved 
after Montelukast. The Canadian Agency Drugs and 
Technologies in Health (2014) says that, according to 
one randomized clinical trial, oral Montelukast appears 
to be effective at improving respiratory disturbances in 
children with mild to moderate obstructive sleep apnea 
as determined by improvements in apnea-hypopnea 
index and obstructive apnea index scores [13]. Few of 
the patients in this study suffered from syncope as a 
symptom, Beckman (2002) states that cough syncope 
occurs primarily in middle-aged male smokers with 
chronic obstructive pulmonary disease. It has also 
been described in children with asthma [14]. Ojo 
and Ozoh (2016) had a case of cough syncope with 
temporary loss of consciousness that lasted for 3 s. 
The patient showed significant improvement after 
being treated with a short course of oral steroids 
and salbutamol as needed and continued on inhaled 
steroids and Montelukast [15]. A study done by French 
et al. about impact of chronic cough on quality of life 
claimed that chronic cough was significantly associated 
with meaningful adverse psychosocial and physical 
effects on quality of life. Compared with individuals 
with no health-related dysfunction, it revealed that 
cough was associated with dysfunction in patients 
usual daily activities, particularly in the categories of 
ambulation, social interaction, sleep and rest, work, 
home management, and recreation [16]. According to 
a study done by Mincheva et al., in 2014, found that 
patients with chronic cough due to upper airway cough 
syndrome or gastroesophageal reflux disease but not 
asthma reported significant relief of their symptoms 
after 2 weeks of treatment with Montelukast [17].
Conclusion
The use of Montelukast leads to reduction 
in the frequency of chronic cough and the symptoms 
associated with it.
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